Therapie 2010-01-01

Safety review: squalene and thimerosal in vaccines.

Marc Montana, Pierre Verhaeghe, Caroline Ducros, Thierry Terme, Patrice Vanelle, Pascal Rathelot

Index: Therapie. 65(6) , 533-41, (2010)

Full Text: HTML

Abstract

Few studies show the reluctance of the people to get vaccinated against A (H1N1) influenza for fear of side effects of squalene (MF59, AS03, AF03) and thimerosal. The aim of this paper is to assess the safety in using these adjuvants and preservative reviewing data of clinical trials relative to which formulation includes these compounds. In the current state of knowledge, these vaccines have proved to be effective even though they more frequently give local adverse events than non-adjuvanted influenza vaccines. Systemic side effects are generally not serious. In the studies, adjuvanted vaccines do not increase neither the risk of Guillain Barre syndrome nor auto-immune diseases. There is no convincing evidence that exposure to thimerosal in vaccines had any deletorious effect on physiological outcome.© 2010 Société Française de Pharmacologie et de Thérapeutique.

Related Compounds

  • Squalene
  • Thiomersal

Related Articles:

The mannoprotein TIR3 (CAGL0C03872g) is required for sterol uptake in Candida glabrata.

2015-02-01

[Biochim. Biophys. Acta 1851(2) , 141-51, (2015)]

Comparison of rheological properties, follicular penetration, drug release, and permeation behavior of a novel topical drug delivery system and a conventional cream.

2014-11-01

[Eur. J. Pharm. Biopharm. 88(3) , 614-24, (2015)]

Identification of a novel hypocholesterolemic protein, major royal jelly protein 1, derived from royal jelly.

2014-01-01

[PLoS ONE 9(8) , e105073, (2014)]

FR171456 is a specific inhibitor of mammalian NSDHL and yeast Erg26p.

2015-01-01

[Nat. Commun. 6 , 8613, (2015)]

Newborn boys and girls differ in the lipid composition of vernix caseosa.

2014-01-01

[PLoS ONE 9(6) , e99173, (2014)]

More Articles...